Fibroblast abnormalities in the pathogenesis of systemic sclerosis

References

• Silver RM. Clinical aspects of localized and systemic scleroderma. Curr. Opin. Rheumatol.3, 973–978 (1991).
   PubMedGoogle Scholar
• LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J. Rheumatol.28, 1573–1576 (2001).
   PubMed Web of Science ®Google Scholar
• Abraham DJ, Varga J. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol.26, 587–595 (2005).
   PubMed Web of Science ®Google Scholar
• Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum.43, 2437–2444 (2000).
   PubMed Web of Science ®Google Scholar
• Arnett FC, Cho M, Chatterjee S, Aguilar MB, Reveille JD, Mayes MD. Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum.44, 1359–1362 (2001).
   PubMed Web of Science ®Google Scholar
• Radstake TR, Gorlova O, Rueda B et al. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat. Genet.42, 426–429 (2010).
   PubMed Web of Science ®Google Scholar
• Dieudé P, Guedj M, Wipff J et al. The PTPN22 620W allele confers susceptibility to systemic sclerosis: findings of a large case-control study of European Caucasians and a meta-analysis. Arthritis Rheum.58, 2183–2188 (2008).
   PubMed Web of Science ®Google Scholar
• Rueda B, Broen J, Simeon C et al. The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype. Hum. Mol. Genet.18, 2071–2077 (2009).
   PubMed Web of Science ®Google Scholar
• Zhou X, Tan FK, Reveille JD et al. Association of novel polymorphisms with the expression of SPARC in normal fibroblasts and with susceptibility to scleroderma. Arthritis Rheum.46, 2990–2999 (2002).
   PubMed Web of Science ®Google Scholar
• Tan FK, Wang N, Kuwana M et al. Association of fibrillin 1 single-nucleotide polymorphism haplotypes with systemic sclerosis in Choctaw and Japanese populations. Arthritis Rheum.44, 893–901 (2001).
   PubMed Web of Science ®Google Scholar
• Fonseca C, Lindahl GE, Ponticos M et al. A polymorphism in the CTGF promoter region associated with systemic sclerosis. N. Engl. J. Med.357, 1210–1220 (2007).
   PubMed Web of Science ®Google Scholar
• Rueda B, Simeon C, Hesselstrand R et al. A large multicenter analysis of CTGF -945 promoter polymorphism does not confirm association with systemic sclerosis susceptibility or phenotype. Ann. Rheum. Dis.68, 1618–1620 (2009).
   PubMedGoogle Scholar
• Rogai V, Lories RJ, Guiducci S, Luyten FP, Matucci Cerinic M. Animal models in systemic sclerosis. Clin. Exp. Rheumatol.26, 941–946 (2008).
   PubMedGoogle Scholar
• LeRoy EC. Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. J. Clin. Invest.54, 880–889 (1974).
   PubMed Web of Science ®Google Scholar
• Hitraya EG, Jiménez SA. Transcriptional activation of the α 1(I) procollagen gene in systemic sclerosis dermal fibroblasts. Role of intronic sequences. Arthritis Rheum.39, 1347–1354 (1996).
   PubMed Web of Science ®Google Scholar
• Jimenez SA, Hitraya E, Varga J. Pathogenesis of scleroderma. Collagen. Rheum. Dis. Clin. North Am.22, 647–674 (1996).
   PubMed Web of Science ®Google Scholar
• Leroy EC. Connective tissue synthesis by scleroderma skin fibroblasts in cell culture. J. Exp. Med.135, 1351–1362 (1972).
   PubMed Web of Science ®Google Scholar
• Botstein GR, Sherer GK, Leroy EC. Fibroblast selection in scleroderma. An alternative model of fibrosis. Arthritis Rheum.25, 189–195 (1982).
   PubMed Web of Science ®Google Scholar
• Jelaska A, Arakawa M, Broketa G, Korn JH. Heterogeneity of collagen synthesis in normal and systemic sclerosis skin fibroblasts. Increased proportion of high collagen-producing cells in systemic sclerosis fibroblasts. Arthritis Rheum.39, 1338–1346 (1996).
   PubMed Web of Science ®Google Scholar
• Jimenez SA, Saitta B. Alterations in the regulation of expression of the α 1(I) collagen gene (COL1A1) in systemic sclerosis (scleroderma). Springer Semin. Immunopathol.21, 397–414 (1999).
   PubMedGoogle Scholar
• Jelaska A, Korn JH. Role of apoptosis and transforming growth factor β1 in fibroblast selection and activation in systemic sclerosis. Arthritis Rheum.43, 2230–2239 (2000).
   PubMed Web of Science ®Google Scholar
• Santiago B, Galindo M, Rivero M, Pablos JL. Decreased susceptibility to Fas induced apoptosis of systemic sclerosis dermal fibroblasts. Arthritis Rheum.44, 1667–1676 (2001).
   PubMed Web of Science ®Google Scholar
• Yamakage A, Kikuchi K, Smith EA, LeRoy EC, Trojanowska M. Selective upregulation of platelet-derived growth factor α receptors by transforming growth factor β in scleroderma fibroblasts. J. Exp. Med.175, 1227–1234 (1992).
   PubMed Web of Science ®Google Scholar
• Whitfield ML, Finlay DR, Murray JI et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc. Natl Acad. Sci. USA100, 12319–12324 (2003).
   PubMed Web of Science ®Google Scholar
• Gardner H, Shearstone JR, Bandaru R et al. Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. Arthritis Rheum.54, 1961–1973 (2006).
   PubMed Web of Science ®Google Scholar
• Kissin EY, Merkel PA, Lafyatis R. Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis. Arthritis Rheum.54, 3655–3660 (2006).
   PubMed Web of Science ®Google Scholar
• Rajkumar VS, Howell K, Csiszar K, Denton CP, Black CM, Abraham DJ. Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res. Ther.7, R1113–R1123 (2005).
   PubMed Web of Science ®Google Scholar
• Farina G, Lemaire R, Pancari P, Bayle J, Widom RL, Lafyatis R. Cartilage oligomeric matrix protein expression in systemic sclerosis reveals heterogeneity of dermal fibroblast responses to transforming growth factor β. Ann. Rheum. Dis.68, 435–441 (2009).
   PubMedGoogle Scholar
• Desmoulière A, Chaponnier C, Gabbiani G. Tissue repair, contraction, and the myofibroblast. Wound Repair Regen.13, 7–12 (2005).
   PubMed Web of Science ®Google Scholar
• Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. The myofibroblast: one function, multiple origins. Am. J. Pathol.170, 1807–1816 (2007).
   PubMed Web of Science ®Google Scholar
• Hu B, Gharaee-Kermani M, Wu Z, Phan SH. Epigenetic regulation of myofibroblast differentiation by DNA methylation. Am. J. Pathol.177, 21–28 (2010).
   PubMedGoogle Scholar
• Chesney J, Bacher M, Bender A, Bucala R. The peripheral blood fibrocyte is a potent antigen-presenting cell capable of priming naive T cells in situ. Proc. Natl Acad. Sci. USA94, 6307–6312 (1997).
   PubMed Web of Science ®Google Scholar
• Abe R, Donnelly SC, Peng T, Bucala R, Metz CN. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J. Immunol.166, 7556–7562 (2001).
   PubMed Web of Science ®Google Scholar
• Shao DD, Suresh R, Vakil V, Gomer RH, Pilling D. Pivotal advance: Th-1 cytokines inhibit, and Th-2 cytokines promote fibrocyte differentiation. J. Leukoc. Biol.83, 1323–1333 (2008)
   PubMed Web of Science ®Google Scholar
• Pilling D, Buckley CD, Salmon M, Gomer RH. Inhibition of fibrocyte differentiation by serum amyloid P. J. Immunol.171, 5537–5546 (2003).
   PubMed Web of Science ®Google Scholar
• Phillips RJ, Burdick MD, Hong K et al. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J. Clin. Invest.114, 438–446 (2004).
   PubMed Web of Science ®Google Scholar
• Schmidt M, Sun G, Stacey MA, Mori L, Mattoli S. Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma. J. Immunol.171, 380–389 (2003).
   PubMed Web of Science ®Google Scholar
• Ortonne N, Lipsker D, Chantrel F, Boehm N, Grosshans E, Cribier B. Presence of CD45RO+ CD34+ cells with collagen syntesis activity in nephrogenic fibrosing dermopathy: a new pathogenic hyphotesis. Br. J. Dermatol.150, 1050–1052 (2004).
   PubMedGoogle Scholar
• Aiba S, Tabata N, Ohtani H, Tagami H. CD34+ spindle-shaped cells selectively disappear from the skin lesion of scleroderma. Arch. Dermatol.130, 593–597 (1994).
   PubMedGoogle Scholar
• Kuwana M, Okazaki Y, Kodama H et al. Human circulating CD14+ monocytes as a source of progenitors that exhibit mesenchymal cell differentiation. J. Leukoc. Biol.74, 833–845 (2003).
   PubMed Web of Science ®Google Scholar
• Postlethwaite AE, Shigemitsu H, Kanangat S. Cellular origins of fibroblasts: possible implications for organ fibrosis in systemic sclerosis. Curr. Opin. Rheumatol.16, 733–738 (2004).
   PubMedGoogle Scholar
• Boban I, Barisic-Dujmovic T, Clark SH. Parabiosis and transplantation models show no evidence of circulating dermal fibroblast progenitors in bleomycin-induced skin fibrosis. J. Cell Physiol.214, 230–237 (2008).
   PubMedGoogle Scholar
• Ishii G, Sangai T, Sugiyama K et al.In vivo characterization of bone marrow-derived fibroblasts recruited into fibrotic lesions. Stem Cells23, 699–706 (2005).
   PubMedGoogle Scholar
• Ortiz LA, Gambelli F, McBride C et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc. Natl Acad. Sci. USA100, 8407–8411 (2003).
   PubMed Web of Science ®Google Scholar
• Ninichuk V, Gross O, Segerer S et al. Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3-deficient mice. Kidney Int.70, 121–129 (2006).
   PubMed Web of Science ®Google Scholar
• Cheng Z, Ou L, Zhou X et al. Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol. Ther.16, 571–579 (2008).
   PubMed Web of Science ®Google Scholar
• Pasha Z, Wang Y, Sheikh R, Zhang D, Zhao T, Ashraf M. Preconditioning enhances cell survival and differentiation of stem cells during transplantation in infarcted myocardium. Cardiovasc. Res.77, 134–142 (2008).
   PubMed Web of Science ®Google Scholar
• Willis BC, Liebler JM, Luby-Phelps K et al. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-β1: potential role in idiopathic pulmonary fibrosis. Am. J. Pathol.166, 1321–1332 (2005).
   PubMed Web of Science ®Google Scholar
• Kim KK, Kugler MC, Wolters PJ et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc. Natl Acad. Sci. USA103, 13180–13185 (2006).
   PubMed Web of Science ®Google Scholar
• Kalluri R, Neilson EG. Epithelial–mesenchymal transition and its implications for fibrosis. J. Clin. Invest.112, 1776–1784 (2003).
   PubMed Web of Science ®Google Scholar
• Zeisberg EM, Tarnavski O, Zeisberg M et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat. Med.13, 952–961 (2007).
   PubMed Web of Science ®Google Scholar
• Rajkumar VS, Sundberg C, Abraham DJ, Rubin K, Black CM. Activation of microvascular pericytes in autoimmune Raynaud’s phenomenon and systemic sclerosis. Arthritis Rheum.42, 930–941 (1999).
   PubMedGoogle Scholar
• Rajkumar VS, Shiwen X, Bostrom M et al. Platelet-derived growth factor-β receptor activation is essential for fibroblast and pericyte recruitment during cutaneous wound healing. Am. J. Pathol.169, 2254–2265 (2006).
   PubMed Web of Science ®Google Scholar
• Gay S, Jones RE Jr, Huang GQ, Gay RE. Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma. J. Invest. Dermatol.92, 301–303 (1989).
   PubMed Web of Science ®Google Scholar
• Zheng XY, Zhang JZ, Tu P, Ma SQ. Expression of platelet-derived growth factor B-chain and platelet-derived growth factor β-receptor in fibroblasts of scleroderma. J. Dermatol. Sci.18, 90–97 (1998).
   PubMedGoogle Scholar
• Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J. Clin. Invest.117, 557–567 (2007).
   PubMed Web of Science ®Google Scholar
• Wynn TA. Fibrotic disease and the T(h)1/T(h)2 paradigm. Nat. Rev. Immunol.4, 583–594 (2004).
   PubMed Web of Science ®Google Scholar
• Distler JH, Jüngel A, Pileckyte M et al. Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. Arthritis Rheum.56, 4203–4215 (2007).
   PubMed Web of Science ®Google Scholar
• Varga J, Pasche B. Transforming growth factor β as a therapeutic target in systemic sclerosis. Nat. Rev. Rheumatol.5, 200–206 (2009).
   PubMed Web of Science ®Google Scholar
• Roberts AB, Sporn MB, Assoian RK et al. Transforming growth factor type β: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc. Natl Acad. Sci. USA83, 4167–4171 (1986).
   PubMed Web of Science ®Google Scholar
• Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor β in human disease. N. Engl. J. Med.342, 1350–1358 (2000).
   PubMed Web of Science ®Google Scholar
• Desmoulière A, Geinoz A, Gabbiani F, Gabbiani G. Transforming growth factor-β induces α smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J. Cell. Biol.122, 103–111 (1993).
   PubMed Web of Science ®Google Scholar
• Kawakami T, Ihn H, Xu W, Smith E, LeRoy C, Trojanowska M. Increased expression of TGF-β receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-β signalling to scleroderma phenotype. J. Invest. Dermatol.110, 47–51 (1998).
   PubMed Web of Science ®Google Scholar
• Asano Y, Ihn H, Yamane K, Jinnin M, Mimura Y, Tamaki K. Involvement of αvβ5 integrin-mediated activation of latent transforming growth factor β1 in autocrine transforming growth factor β signalling in systemic sclerosis fibroblasts. Arthritis Rheum.52, 2897–2905 (2005).
   PubMed Web of Science ®Google Scholar
• Kubo M, Ihn H, Yamane K, Tamaki K. Upregulated expression of transforming growth factor-β receptors in dermal fibroblasts of skin sections from patients with systemic sclerosis. J. Rheumatol.29, 2558–2564 (2002).
   PubMed Web of Science ®Google Scholar
• Mori Y, Chen SJ, Varga J. Expression and regulation of intracellular SMAD signalling in scleroderma skin fibroblasts. Arthritis Rheum.48, 1964–1978 (2003).
   PubMed Web of Science ®Google Scholar
• Dong C, Zhu S, Wang T et al. Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc. Natl Acad. Sci. USA99, 3908–3913 (2002).
   PubMed Web of Science ®Google Scholar
• Jinnin M, Ihn H, Mimura Y, Asano Y, Tamaki K. Involvement of the constitutive complex formation of c-Ski/SnoN with Smads in the impaired negative feedback regulation of transforming growth factor β signalling in scleroderma fibroblasts. Arthritis Rheum.56, 1694–1705 (2007).
   PubMedGoogle Scholar
• Ishida W, Mori Y, Lakos G et al. Intracellular TGF-β receptor blockade abrogates Smad-dependent fibroblast activation in vitro and in vivo. J. Invest. Dermatol.126, 1733–1744 (2006).
   PubMed Web of Science ®Google Scholar
• Del Galdo F, Sotgia F, de Almeida CJ et al. Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis. Arthritis Rheum.58, 2854–2865 (2008).
   PubMed Web of Science ®Google Scholar
• Tan FK, Hildebrand BA, Lester MS et al. Classification analysis of the transcriptosome of nonlesional cultured dermal fibroblasts from systemic sclerosis patients with early disease. Arthritis Rheum.52, 865–876 (2005).
   PubMed Web of Science ®Google Scholar
• Massague J. TGF-β signal transduction. Annu. Rev. Biochem.67, 753–791 (1998).
   PubMed Web of Science ®Google Scholar
• Moustakas A, Heldin CH. Non-Smad TGF-β signals. J. Cell. Sci.118, 3573–3584 (2005).
   PubMed Web of Science ®Google Scholar
• Chung L, Fiorentino DF, Benbarak MJ et al. Molecular framework for response to imatinib mesylate in systemic sclerosis. Arthritis Rheum.60, 584–591 (2009).
   PubMed Web of Science ®Google Scholar
• Distler JH, Jüngel A, Huber LC et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum.56, 311–322 (2007).
   PubMed Web of Science ®Google Scholar
• Akhmetshina A, Dees C, Pileckyte M et al. Dual inhibition of c-abl and PDGF receptor signalling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J.22, 2214–2222 (2008).
   PubMed Web of Science ®Google Scholar
• Pannu J, Asano Y, Nakerakanti S et al. Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate. Arthritis Rheum.58, 2528–2537 (2008).
   PubMed Web of Science ®Google Scholar
• Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Tamaki K. Constitutive phosphorylation of focal adhesion kinase is involved in the myofibroblast differentiation of scleroderma fibroblasts. J. Invest. Dermatol.124, 886–892 (2005).
   PubMedGoogle Scholar
• Jun JB, Kuechle M, Min J et al. Scleroderma fibroblasts demonstrate enhanced activation of Akt (protein kinase B) in situ. J. Invest. Dermatol.124, 298–303 (2005).
   PubMedGoogle Scholar
• Ihn H, Yamane K, Tamaki K. Increased phosphorylation and activation of mitogen-activated protein kinase p38 in scleroderma fibroblasts. J. Invest. Dermatol.125, 247–255 (2005).
   PubMedGoogle Scholar
• Sato M, Shegogue D, Gore EA, Smith EA, McDermott PJ, Trojanowska M. Role of p38 MAPK in transforming growth factor β stimulation of collagen production by scleroderma and healthy dermal fibroblasts. J. Invest. Dermatol.118, 704–711 (2002).
   PubMedGoogle Scholar
• Wu M, Melichian DS, de la Garza M et al. Essential roles for early growth response transcription factor Egr-1 in tissue fibrosis and wound healing. Am. J. Pathol.175, 1041–1055 (2009).
   PubMed Web of Science ®Google Scholar
• Bhattacharyya S, Wei J, Melichian DS, Milbrandt J, Takehara K, Varga J. The transcriptional cofactor Nab2 is induced by TGF-β and suppresses fibroblast activation: physiological roles and impaired expression in scleroderma. PLoS ONE26(4), e7620 (2009).
   Google Scholar
• Abraham D, Distler O. How does endothelial cell injury start? The role of endothelin in systemic sclerosis. Arthritis Res. Ther.9(Suppl. 2), S2 (2007).
   Google Scholar
• Shi-wen X, Kennedy L, Renzoni EA et al. Endothelin is a downstream mediator of pro-fibrotic responses to transforming growth factor β in human lung fibroblasts. Arthritis Rheum.56, 4189–4194 (2007).
   PubMed Web of Science ®Google Scholar
• Denton CP, Abraham DJ. Transforming growth factor-β and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr. Opin. Rheumatol.13, 505–511 (2001).
   PubMed Web of Science ®Google Scholar
• Stratton R, Shiwen X, Martini G et al. Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J. Clin. Invest.108, 241–250 (2001).
   PubMed Web of Science ®Google Scholar
• Baroni SS, Santillo M, Bevilacqua F et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N. Engl. J. Med.354, 2667–2676 (2006).
   PubMed Web of Science ®Google Scholar
• Classen JF, Henrohn D, Rorsman F et al. Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis. Arthritis Rheum.60, 1137–1144 (2009).
   PubMed Web of Science ®Google Scholar
• Loizos N, Lariccia L, Weiner J et al. Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor α in a subset of normal and systemic sclerosis patient sera. Arthritis Rheum.60, 1145–1151 (2009).
   PubMedGoogle Scholar
• Hogaboam CM, Bone-Larson CL, Lipinski S et al. Differential monocyte chemoattractant protein-1 and chemokine receptor 2 expression by murine lung fibroblasts derived from Th1- and Th2-type pulmonary granuloma models. J. Immunol.163, 2193–2201 (1999).
   PubMedGoogle Scholar
• Chizzolini C, Parel Y, Scheja A, Dayer JM. Polarized subsets of human T-helper cells induce distinct patterns of chemokine production by normal and systemic sclerosis dermal fibroblasts. Arthritis Res. Ther.8, R10 (2006).
   Google Scholar
• Galindo M, Santiago B, Rivero M, Rullas J, Alcami J, Pablos JL. Chemokine expression by systemic sclerosis fibroblasts: abnormal regulation of monocyte chemoattractant protein 1 expression. Arthritis Rheum.44, 1382–1386 (2001).
   PubMedGoogle Scholar
• Distler JH, Jüngel A, Caretto D et al. Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its pro-fibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. Arthritis Rheum.54, 214–225 (2006).
   PubMedGoogle Scholar
• Granstein RD, Flotte TJ, Amento EP. Interferons and collagen production. J. Invest. Dermatol.95, 75S–80S (1990).
   PubMed Web of Science ®Google Scholar
• Desmoulière A, Rubbia-Brandt L, Abdiu A, Walz T, Macieira-Coelho A, Gabbiani G. A-smooth muscle actin is expressed in a subpopulation of cultured and cloned fibroblasts and is modulated by γ-interferon. Exp. Cell. Res.201, 64–73 (1992).
   PubMed Web of Science ®Google Scholar
• Santiago B, Galindo M, Palao G, Pablos JL. Intracellular regulation of Fas-induced apoptosis in human fibroblasts by extracellular factors and cycloheximide. J. Immunol.172, 560–566 (2004).
   PubMedGoogle Scholar
• Lemaire R, Farina G, Bayle J et al. Antagonistic effect of the matricellular signalling protein CCN3 on TGF-β- and Wnt-mediated fibrillinogenesis in systemic sclerosis and Marfan syndrome. J. Invest. Dermatol.130, 1514–1523 (2010).
   PubMed Web of Science ®Google Scholar
• Castelino FV, Seiders J, Bain G et al. Genetic deletion or pharmacologic antagonism of LPA(1) ameliorates dermal fibrosis in a scleroderma mouse model. Arthritis Rheum.63(5), 1405–1415 (2011).
   PubMed Web of Science ®Google Scholar
• Oga T, Matsuoka T, Yao C et al. Prostaglandin F(2α) receptor signalling facilitates bleomycin-induced pulmonary fibrosis independently of transforming growth factor-β. Nat. Med.15, 1426–1430 (2009).
   PubMed Web of Science ®Google Scholar
• Shi-wen X, Eastwood M, Stratton RJ, Denton CP, Leask A, Abraham DJ. Rosiglitazone alleviates the persistent fibrotic phenotype of lesional skin scleroderma fibroblasts. Rheumatology (Oxford).49, 259–263 (2010).
   PubMed Web of Science ®Google Scholar
• Wu M, Melichian DS, Chang E, Warner-Blankenship M, Ghosh AK, Varga J. Rosiglitazone abrogates bleomycin-induced scleroderma and blocks pro-fibrotic responses through peroxisome proliferator-activated receptor-γ. Am. J. Pathol.174, 519–533 (2009).
   PubMed Web of Science ®Google Scholar
• Maurer B, Stanczyk J, Jüngel A et al. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum.62, 1733–1743 (2010).
   PubMed Web of Science ®Google Scholar
• Wang Y, Fan PS, Kahaleh B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum.54, 2271–2279 (2006).
   PubMed Web of Science ®Google Scholar
• Kubo M, Czuwara-Ladykowska J, Moussa O et al. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am. J. Pathol.163, 571–578 (2003).
   PubMedGoogle Scholar